Background: Primary Immunodeficiencies (PIDs) are a heterogeneous group of genetic immune disorders. While some PIDs can manifest with more than one phenotype, signs, and symptoms of various PIDs overlap considerably. Recently, novel defects in immune-related genes and additional variants in previously reported genes responsible for PIDs have been successfully identified by Next Generation Sequencing (NGS), allowing the recognition of a broad spectrum of disorders. Objective: To evaluate the strength and weakness of targeted NGS sequencing using custom-made Ion Torrent and Haloplex (Agilent) panels for diagnostics and research purposes. Methods: Five different panels including known and candidate genes were used to screen 105 patients with distinct PID features divided in three main PID categories: T cell defects, Humoral defects and Other PIDs. The Ion Torrent sequencing platform was used in 73 patients. Among these, 18 selected patients without a molecular diagnosis and 32 additional patients were analyzed by Haloplex enrichment technology. Results: The complementary use of the two custom-made targeted sequencing approaches allowed the identification of causative variants in 28.6% (n = 30) of patients. Twenty-two out of 73 (34.6%) patients were diagnosed by Ion Torrent. In this group 20 were included in the SCID/CID category. Eight out of 50 (16%) patients were diagnosed by Haloplex workflow. Ion Torrentmethod was highly successful for those cases with welldefined phenotypes for immunological and clinical presentation. The Haloplex approach was able to diagnose 4 SCID/CID patients and 4 additional patients with complex and extended phenotypes, embracing all three PID categories in which this approach was more efficient. Both technologies showed good gene coverage. Conclusions: NGS technology represents a powerful approach in the complex field of rare disorders but its different application should be weighted. A relatively small NGS target panel can be successfully applied for a robust diagnostic suspicion, while when the spectrum of clinical phenotypes overlaps more than one PID an in-depth NGS analysis is required, including also whole exome/genome sequencing to identify the causative gene.

Targeted NGS Platforms for Genetic Screening and Gene Discovery in Primary Immunodeficiencies / Cifaldi, Cristina; Brigida, Immacolata; Barzaghi, Federica; Zoccolillo, Matteo; Ferradini, Valentina; Petricone, Davide; Cicalese, MARIA PIA; Lazarevic, Dejan; Cittaro, Davide; Omrani, Maryam; Attardi, Enrico; Conti, Francesca; Scarselli, Alessia; Chiriaco, Maria; Di Cesare, Silvia; Licciardi, Francesco; Davide, Montin; Ferrua, Francesca; Canessa, Clementina; Pignata, Claudio; Giliani, Silvia; Ferrari, Simona; Fousteri, Georgia; Barera, Graziano; Merli, Pietro; Palma, Paolo; Cesaro, Simone; Gattorno, Marco; Trizzino, Antonio; Moschese, Viviana; Chini, Loredana; Villa, Anna; Azzari, Chiara; Finocchi, Andrea; Locatelli, Franco; Rossi, Paolo; Sangiuolo, Federica; Aiuti, Alessandro; Cancrini and Gigliola Di Matteo, Caterina. - In: FRONTIERS IN IMMUNOLOGY. - ISSN 1664-3224. - 10:(2019), pp. 1-19. [10.3389/fimmu.2019.00316]

Targeted NGS Platforms for Genetic Screening and Gene Discovery in Primary Immunodeficiencies

Maria Pia Cicalese;Francesca Conti;Claudio Pignata;Viviana Moschese;Franco Locatelli;Paolo Rossi;
2019

Abstract

Background: Primary Immunodeficiencies (PIDs) are a heterogeneous group of genetic immune disorders. While some PIDs can manifest with more than one phenotype, signs, and symptoms of various PIDs overlap considerably. Recently, novel defects in immune-related genes and additional variants in previously reported genes responsible for PIDs have been successfully identified by Next Generation Sequencing (NGS), allowing the recognition of a broad spectrum of disorders. Objective: To evaluate the strength and weakness of targeted NGS sequencing using custom-made Ion Torrent and Haloplex (Agilent) panels for diagnostics and research purposes. Methods: Five different panels including known and candidate genes were used to screen 105 patients with distinct PID features divided in three main PID categories: T cell defects, Humoral defects and Other PIDs. The Ion Torrent sequencing platform was used in 73 patients. Among these, 18 selected patients without a molecular diagnosis and 32 additional patients were analyzed by Haloplex enrichment technology. Results: The complementary use of the two custom-made targeted sequencing approaches allowed the identification of causative variants in 28.6% (n = 30) of patients. Twenty-two out of 73 (34.6%) patients were diagnosed by Ion Torrent. In this group 20 were included in the SCID/CID category. Eight out of 50 (16%) patients were diagnosed by Haloplex workflow. Ion Torrentmethod was highly successful for those cases with welldefined phenotypes for immunological and clinical presentation. The Haloplex approach was able to diagnose 4 SCID/CID patients and 4 additional patients with complex and extended phenotypes, embracing all three PID categories in which this approach was more efficient. Both technologies showed good gene coverage. Conclusions: NGS technology represents a powerful approach in the complex field of rare disorders but its different application should be weighted. A relatively small NGS target panel can be successfully applied for a robust diagnostic suspicion, while when the spectrum of clinical phenotypes overlaps more than one PID an in-depth NGS analysis is required, including also whole exome/genome sequencing to identify the causative gene.
2019
Targeted NGS Platforms for Genetic Screening and Gene Discovery in Primary Immunodeficiencies / Cifaldi, Cristina; Brigida, Immacolata; Barzaghi, Federica; Zoccolillo, Matteo; Ferradini, Valentina; Petricone, Davide; Cicalese, MARIA PIA; Lazarevic, Dejan; Cittaro, Davide; Omrani, Maryam; Attardi, Enrico; Conti, Francesca; Scarselli, Alessia; Chiriaco, Maria; Di Cesare, Silvia; Licciardi, Francesco; Davide, Montin; Ferrua, Francesca; Canessa, Clementina; Pignata, Claudio; Giliani, Silvia; Ferrari, Simona; Fousteri, Georgia; Barera, Graziano; Merli, Pietro; Palma, Paolo; Cesaro, Simone; Gattorno, Marco; Trizzino, Antonio; Moschese, Viviana; Chini, Loredana; Villa, Anna; Azzari, Chiara; Finocchi, Andrea; Locatelli, Franco; Rossi, Paolo; Sangiuolo, Federica; Aiuti, Alessandro; Cancrini and Gigliola Di Matteo, Caterina. - In: FRONTIERS IN IMMUNOLOGY. - ISSN 1664-3224. - 10:(2019), pp. 1-19. [10.3389/fimmu.2019.00316]
File in questo prodotto:
File Dimensione Formato  
FronImmunol2019.pdf

accesso aperto

Tipologia: Documento in Post-print
Licenza: Dominio pubblico
Dimensione 1.32 MB
Formato Adobe PDF
1.32 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/750148
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 34
  • ???jsp.display-item.citation.isi??? 34
social impact